What prior CLNN share sales by Symbiosis II LLC are disclosed in this Form 144?

The filing lists numerous prior open-market sales of CLNN shares since December 2025. It details daily transactions by Symbiosis II LLC from 12/03/2025 through 01/29/2026, including the number of common shares sold and gross proceeds for each sale.

Symbiosis II LLC plans sale of 60,842 CLNN shares

Q: How many CLNN shares is Symbiosis II LLC planning to sell under this Form 144?

Symbiosis II LLC plans to sell 60,842 CLNN common shares. The notice shows these shares have an aggregate market value of $265,731 and are to be sold on Nasdaq through Merrill Lynch, compared with 10,333,980 Clene shares outstanding.

Clene Inc. insider Symbiosis II LLC has filed a notice to sell 60,842 shares of CLNN common stock.

Accepted by SEC EDGAR 02/03/2026 - 03:36 PM EST

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

144

Rhea-AI Filing Summary

Clene Inc. insider Symbiosis II LLC has filed a notice to sell 60,842 shares of CLNN common stock. The planned sale, through Merrill Lynch on Nasdaq around 01/29/2026, has an aggregate market value of $265,731, compared with 10,333,980 shares outstanding.

The shares were acquired on 06/20/2023 via an open-market purchase for cash. The filing also lists numerous prior open-market sales by Symbiosis II LLC from December 2025 through January 29, 2026, with gross proceeds disclosed for each trade. The seller represents it is not aware of undisclosed material adverse information about Clene.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the CLNN Form 144 filing by Symbiosis II LLC disclose?

The filing discloses a planned sale of 60,842 Clene (CLNN) common shares. Symbiosis II LLC intends to sell these shares through Merrill Lynch on Nasdaq, with an aggregate market value of $265,731, and confirms it knows no undisclosed material adverse information about Clene.

How many CLNN shares is Symbiosis II LLC planning to sell under this Form 144?

Symbiosis II LLC plans to sell 60,842 CLNN common shares. The notice shows these shares have an aggregate market value of $265,731 and are to be sold on Nasdaq through Merrill Lynch, compared with 10,333,980 Clene shares outstanding.

When and how did Symbiosis II LLC acquire the CLNN shares it now plans to sell?

The shares were acquired on June 20, 2023 via an open-market purchase. The table states Symbiosis II LLC acquired 60,842 Clene common shares from the issuer on 06/20/2023, paying the purchase price in cash on the same date.

What representation does the CLNN Form 144 filer make about inside information?

The filer represents it is not aware of undisclosed material adverse information about Clene. By signing, the person for whose account the securities are sold affirms no knowledge of non-public negative information regarding Clene’s current or prospective operations.

Through which broker and exchange will the CLNN shares be sold under this notice?

The planned CLNN share sale will be executed through Merrill Lynch on Nasdaq. The securities information table identifies Merrill Lynch’s San Francisco office as broker, specifies the common stock class, and names Nasdaq as the securities exchange for the intended transactions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

144: Filer Information

Filer CIK

0002006045

Filer CCC

XXXXXXXX

Is this a LIVE or TEST Filing?

LIVE TEST

Submission Contact Information

Name

Phone

E-Mail Address

144: Issuer Information

Name of Issuer

Clene Inc

SEC File Number

001-39834

Address of Issuer

6550 South Millrock Drive
Suite G50
Salt Lake City
UTAH
84121

Phone

8016769695

Name of Person for Whose Account the Securities are To Be Sold

Symbiosis II LLC

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Prior board member

144: Securities Information

Title of the Class of Securities To Be Sold

Name and Address of the Broker

Number of Shares or Other Units To Be Sold

Aggregate Market Value

Number of Shares or Other Units Outstanding

Approximate Date of Sale

Name the Securities Exchange

Common

Merrill Lynch
555 California St
Ste 1800
San Francisco CA 94104

60842

265731

10333980

01/29/2026

Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class

Date you Acquired

Nature of Acquisition Transaction

Name of Person from Whom Acquired

Is this a Gift?

Date Donor Acquired

Amount of Securities Acquired

Date of Payment

Nature of Payment *

Common

06/20/2023

Open Market Purchase

Issuer

60842

06/20/2023

Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller

Title of Securities Sold

Date of Sale

Amount of Securities Sold

Gross Proceeds